Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii61-4.

Disease activity assessment in SLE: do we have the right instruments?

Author information

1
Johns Hopkins University School of Medicine, Division of Rheumatology, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA. mpetri@jhmi.edu

Abstract

No new therapy has been approved for systemic lupus erythematosus (SLE) in decades. Interest in SLE by pharmaceutical and biotechnology companies has increased, leading to multiple clinical trials. Unfortunately, we have now compiled quite a long list of "failed" trials. If this was due to the fact that the studied therapy did not work in SLE, we could accept it and move on. Of concern, however, is that many of the "failed" treatments had a strong "signal" of efficacy, often in subgroup analyses that made logical sense, given what was known about the mechanism of action of the treatment. This has led, understandably, to concern that there is something wrong with SLE trial designs, particularly with SLE disease activity indices.

PMID:
17934099
PMCID:
PMC2095289
DOI:
10.1136/ard.2007.078477
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center